US Patent

US7649019 — Modified release formulations of a bupropion salt

Formulation · Assigned to Biovail Laboratories International SRL · Expires 2026-06-27 · 0y remaining

Vulnerability score 65/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects modified-release formulations of bupropion hydrobromide, specifically modified-release tablets.

USPTO Abstract

The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.

Drugs covered by this patent

bupropion-hydrobromide (BUPROPION HYDROBROMIDE)

Patent Metadata

Patent number: US7649019
Jurisdiction: US
Classification: Formulation
Expires: 2026-06-27
Drug substance claim: No
Drug product claim: Yes
Assignee: Biovail Laboratories International SRL
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.